Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $43.67 Consensus Target Price from Analysts

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $41.60.

Separately, Zacks Investment Research upgraded Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Thursday, September 9th.

Shares of NASDAQ ITCI traded down $0.64 during trading on Tuesday, reaching $32.77. The stock had a trading volume of 235,152 shares, compared to its average volume of 531,846. The company has a market cap of $2.67 billion, a P/E ratio of -10.88 and a beta of 1.29. The business’s 50-day moving average price is $34.15 and its 200-day moving average price is $35.62. Intra-Cellular Therapies has a fifty-two week low of $22.92 and a fifty-two week high of $44.80.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Sunday, August 8th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.06). The company had revenue of $20.00 million during the quarter, compared to analyst estimates of $19.04 million. Intra-Cellular Therapies had a negative net margin of 425.79% and a negative return on equity of 37.50%. The business’s revenue was up 952.6% on a year-over-year basis. Research analysts expect that Intra-Cellular Therapies will post -3.32 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Intra-Cellular Therapies by 1.6% during the second quarter. Vanguard Group Inc. now owns 6,828,437 shares of the biopharmaceutical company’s stock valued at $278,737,000 after acquiring an additional 106,744 shares during the period. Wasatch Advisors Inc. increased its stake in shares of Intra-Cellular Therapies by 3.0% during the first quarter. Wasatch Advisors Inc. now owns 6,525,323 shares of the biopharmaceutical company’s stock valued at $221,405,000 after acquiring an additional 191,423 shares during the period. BlackRock Inc. increased its stake in shares of Intra-Cellular Therapies by 4.4% during the first quarter. BlackRock Inc. now owns 6,158,133 shares of the biopharmaceutical company’s stock valued at $208,946,000 after acquiring an additional 259,565 shares during the period. Lord Abbett & CO. LLC grew its position in Intra-Cellular Therapies by 1.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,145,588 shares of the biopharmaceutical company’s stock worth $87,583,000 after buying an additional 23,448 shares during the last quarter. Finally, State Street Corp grew its position in Intra-Cellular Therapies by 1.1% in the second quarter. State Street Corp now owns 1,500,029 shares of the biopharmaceutical company’s stock worth $61,231,000 after buying an additional 16,370 shares during the last quarter. Institutional investors and hedge funds own 81.80% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.

Read More: Bond

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.